NEW RESEARCH NOTE JUST RELEASED - 156P!!!!4 Jan 2024 16:26
Research Note just out from Logica2me Investments.
Research Note: ANGLE plc Breakthrough in DNA Molecular Analysis of Cancer Patient Blood Samples
Summary:
ANGLE plc has achieved groundbreaking clinical results through the combined analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) using its Parsortix system. The analysis, conducted on forty-seven patient samples across breast, lung, prostate, and ovarian cancers, revealed actionable DNA variants in CTCs not present in ctDNA, offering a unique insight into cancer progression.
Key Findings:
Clinical Significance: The analysis demonstrated the ability to identify actionable DNA variants in CTCs, not present in ctDNA, in 70% of breast cancer samples, 70% of lung cancer samples, and 60% of ovarian cancer samples. These variants included targets for FDA-approved cancer drugs.
Therapeutic Implications: Molecular profiling of CTC-DNA alongside ctDNA may revolutionize cancer treatment by informing treatment decisions, monitoring response to therapy, highlighting drug resistance, and signaling disease progression.
Product and Pharma Services Growth: ANGLE anticipates an increase in product and pharma services sales as a result of these breakthrough results. The company has developed a sample-to-answer molecular solution for real-time Next Generation Sequencing (NGS) DNA analysis.
Unique Insight: The Parsortix system's ability to analyze CTCs and ctDNA from the same blood sample provides a new and unique insight into cancer clonal evolution. This approach could support routine repeat blood tests for tracking cancer progression.
Future Prospects: ANGLE plans to leverage these clinical results to offer sample-to-answer DNA molecular solutions to pharma services customers. The company aims to work with key opinion leaders and clinicians to expedite clinical adoption and conduct further studies.
Potential Extensions: Beyond DNA analysis, the CTC samples offer the potential for extended analysis into RNA, protein, and morphological aspects, making intact living cancer cells (CTCs) a valuable sample for personalized care.
ANGLE's breakthrough represents a critical step in demonstrating the clinical value of NGS molecular analysis on living cancer cells harvested from patient blood samples, potentially transforming cancer diagnosis and treatment.
Verdict: STRONG BUY
Price target 156p
Sign In
Follow the stocks
